Amanda Farrell

Safespaces

Safespaces has been providing safe rooms and high sided beds for people with complex needs since 2001. Amanda''s role as a Product Advisor brings her into daily contact with health and education professionals, parents and carers, who are seeking solutions for issues affecting adults & children with a wide range of needs.

She will share her experience with case studies, showing how effective solutions can be identified. Amanda has a background in product development and training.

dont miss

Safe beds for brain injury, complex needs and challenging behaviours

Reducing risk by providing a safe and appropriate environment to allow access to treatment for those with brain injury, complex needs, movement disorders, challenging behaviours or lack of awareness, can be difficult.
CIPOLD (2013) advocated “reasonable adjustments” so people with complex needs can “effectively access delivery of care”. We explain how specialist safe beds can provide access to care environments for treatment, rehabilitation or therapeutic work and reduce health inequalities.

EVEN MORE SEMINARS

  • Jennifer Legler, BS, CNIM: Speaking at the European Neurological Convention

    Jennifer Legler, BS, CNIM
    Trusted Neurodiagnostics Academy, LLC

    The Importance of Education and Training in Neurodiagnostics

  • Bernhard Haas: Speaking at the European Neurological Convention

    Bernhard Haas
    Plymouth University

    How to make exercise work – barriers, facilitators and motivators

  • Dr Tacson Fernandez: Speaking at the European Neurological Convention

    Dr Tacson Fernandez
    Royal National Orthopaedic Hospital

    Spinal cord stimulation in complex pain patient groups

  • Tamsin Reed: Speaking at the European Neurological Convention

    Tamsin Reed
    Wellington Hospital, London

    Maximising outcomes using advanced technology in Neurological Rehabilitation.

  • Tina Soulis: Speaking at the European Neurological Convention

    Tina Soulis
    Neuroscience Trials Australia

    Strategies in CNS Drug and Device Development: The Australian Advantage